NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast, where he discussed the company’s mission to revolutionize antiviral treatment through its nanoviricide platform and highlighted progress of lead drug candidate NV-387. During the interview, Dr. Diwan explained how nanoviricides are designed to prevent viral escape, function independently of patient immune status, and offer broad-spectrum potential across patient populations, from infants to geriatrics.
He noted that NV-387 has demonstrated efficacy against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles, and has completed a Phase I clinical trial with no reported adverse events. Dr. Diwan added that a Phase II clinical trial for NV-387 targeting MPox is ready to begin in the Democratic Republic of Congo following regulatory clearance, positioning the candidate as a potential empirical therapy for acute respiratory and other viral infections with an estimated market opportunity exceeding $17 billion by 2030.
The interview underscores NanoViricides' progress in advancing NV-387 through clinical development. The drug candidate's broad-spectrum activity and favorable safety profile in Phase I represent significant milestones for the company. The planned Phase II trial in the DRC for MPox could provide critical efficacy data, potentially opening the door for use against other viral diseases. The company's nanoviricide platform, based on technology licensed from TheraCour Pharma, Inc., aims to create novel nanomaterials that mimic host cell receptors to trap and neutralize viruses.
NanoViricides' business model relies on licensing technology from TheraCour for specific antiviral applications. The company holds exclusive licenses for several viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, and Coronaviruses. The broad-spectrum potential of NV-387 is particularly noteworthy given the ongoing need for effective treatments against emerging viral threats and the limitations of existing antiviral drugs, which often target specific viruses and can be rendered ineffective by viral mutations.
The market opportunity for broad-spectrum antivirals is substantial, with the global antiviral drugs market projected to grow significantly. If NV-387 proves safe and effective in Phase II trials, it could address unmet medical needs across multiple viral indications. However, as with all drug development, there are risks, including the possibility that NV-387 may not show sufficient efficacy in clinical trials or may face regulatory hurdles. The company has acknowledged these risks in its disclosures.
For more information on NanoViricides and its pipeline, visit the company’s newsroom at https://ibn.fm/NNVC. The full press release regarding the podcast interview is available at https://ibn.fm/EqHoVA.
